Wechalekar MD - Search Results

1

IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.

Hong LE, Wechalekar MD, Kutyna M, Small A, Lim K, Thompson-Peach C, Li JJ, Chhetri R, Scott HS, Brown A, Hahn CN, Yeung DT, Sajid S, Robinson N, Thomas R, Branford S, D'Andrea RJ, Samaraweera SE, Patnaik M, Proudman S, Thomas D, Kok CH, Shah MV, Hiwase DK. Hong LE, et al. Among authors: wechalekar md. Blood. 2024 May 2;143(18):1873-1877. doi: 10.1182/blood.2023023593. Blood. 2024. PMID: 38457663 Free article.

2

Synovial biopsies in inflammatory arthritis: precision medicine in rheumatoid arthritis.

Small A, Wechalekar MD. Small A, et al. Among authors: wechalekar md. Expert Rev Mol Diagn. 2020 Mar;20(3):315-325. doi: 10.1080/14737159.2020.1707671. Epub 2020 Jan 7. Expert Rev Mol Diagn. 2020. PMID: 31865803 Review.

3

Immune checkpoints in rheumatoid arthritis: progress and promise.

Small A, Lowe K, Wechalekar MD. Small A, et al. Among authors: wechalekar md. Front Immunol. 2023 Nov 24;14:1285554. doi: 10.3389/fimmu.2023.1285554. eCollection 2023. Front Immunol. 2023. PMID: 38077329 Free PMC article. Review.

4

Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients.

Wabe N, Lee A, Wechalekar M, McWilliams L, Proudman S, Wiese M. Wabe N, et al. Int J Clin Pract. 2019 Jul;73(7):e13375. doi: 10.1111/ijcp.13375. Epub 2019 Jun 5. Int J Clin Pract. 2019. PMID: 31120169

5

Editorial: Synovial pathobiology and pathogenesis of inflammatory arthritis.

Small A, Humby F, Wechalekar MD. Small A, et al. Among authors: wechalekar md. Front Med (Lausanne). 2022 Aug 16;9:1008562. doi: 10.3389/fmed.2022.1008562. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36052336 Free PMC article. No abstract available.

6

Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users.

Wabe N, Lee A, Wechalekar M, McWilliams L, Proudman S, Wiese M. Wabe N, et al. Rheumatol Int. 2017 Jun;37(6):897-904. doi: 10.1007/s00296-017-3655-z. Epub 2017 Feb 3. Rheumatol Int. 2017. PMID: 28160071

7

Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis.

Brown Z, Metcalf R, Bednarz J, Spargo L, Lee A, Hill C, Wechalekar M, Stavrou C, James M, Cleland L, Proudman S. Brown Z, et al. ACR Open Rheumatol. 2020 Jun;2(6):371-377. doi: 10.1002/acr2.11132. Epub 2020 May 26. ACR Open Rheumatol. 2020. PMID: 32453505 Free PMC article.

8

Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis.

Reid AB, Wiese M, McWilliams L, Metcalf R, Hall C, Lee A, Hill C, Wechalekar M, Cleland L, Proudman SM. Reid AB, et al. Intern Med J. 2020 Jul;50(7):818-822. doi: 10.1111/imj.14463. Intern Med J. 2020. PMID: 32656986

9

Differential expansion of T peripheral helper cells in early rheumatoid arthritis and osteoarthritis synovium.

Murray-Brown W, Guo Y, Small A, Lowe K, Weedon H, Smith MD, Lester SE, Proudman SM, Rao NL, Hao LY, Nagpal S, Wechalekar MD. Murray-Brown W, et al. Among authors: wechalekar md. RMD Open. 2022 Oct;8(2):e002563. doi: 10.1136/rmdopen-2022-002563. RMD Open. 2022. PMID: 36270740 Free PMC article.

10

Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment.

Lowe K, Small A, Song Q, Hao LY, Murray-Brown W, Proudman S, Smith MD, Nagpal S, Wechalekar MD. Lowe K, et al. Among authors: wechalekar md. Sci Rep. 2023 Feb 17;13(1):2847. doi: 10.1038/s41598-023-29971-5. Sci Rep. 2023. PMID: 36801909 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page